RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen to $350 from $335 and keeps an Outperform rating on the shares. The firm’s recently conducted proprietary physician survey on perceptions of zuranolone ahead of the upcoming launch has left the analyst with greater confidence that physicians are appreciating its differentiated mechanism of action and rapidity of onset, RBC tells investors in a research note. The firm models $1.9B/$200M peak end-user sales potential in MDD/PPD while also increasing its probability of success estimate to 75%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Appoints Chuck Triano as Head of Investor Relations
- Needham healthcare analyst to hold an analyst/industry conference call
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
- Biogen elects Dorsa as Chair of the Board of Directors
- Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors